Literature DB >> 34118786

Mortality of right ventricular dysfunction in patients with acute respiratory distress syndrome subjected to lung protective ventilation: A systematic review and meta-analysis.

Daoran Dong1, Yuan Zong2, Zhuo Li2, Yan Wang2, Chengqiao Jing2.   

Abstract

BACKGROUND: The impact of right ventricular dysfunction(RVD) on the prognosis of acute respiratory distress syndrome(ARDS) patients is controversial.
OBJECTIVES: The objectives of this systematic review and meta-analysis was to investigate whether RVD or pulmonary vascular dysfunction are associated with increased mortality in patients with ARDS.
METHODS: We searched Pubmed, Embase, Cochrane Library, Wanfang Data, CNKI, and the WHO Clinical Trial Registry for studies of RVD or pulmonary vascular dysfunction in patients with ARDS.
RESULTS: The presence of RVD or pulmonary vascular dysfunction in patients with ARDS was associated with an increase in mortality (OR = 1.68, 95% CI = 1.21-2.32, P = 0.069, I2 = 40.8%). Subgroup analyses obtained similar results. Funnel plots and the Egger's test indicated no publication bias, and sensitivity analyses determined that the results were stable.
CONCLUSION: The prognosis of patients with ARDS and RVD or pulmonary vascular dysfunction is worse than that of ARDS patients without RVD or pulmonary vascular dysfunction.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute cor pulmonale; Acute respiratory distress syndrome; Prognosis; Pulmonary vascular dysfunction; Right ventricular dysfunction

Year:  2021        PMID: 34118786     DOI: 10.1016/j.hrtlng.2021.04.011

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  1 in total

1.  Right ventricular failure is strongly associated with mortality in patients with moderate-to-severe COVID-19-related ARDS and appears related to respiratory worsening.

Authors:  Bruno Evrard; Marine Goudelin; Bruno Giraudeau; Bruno François; Philippe Vignon
Journal:  Intensive Care Med       Date:  2022-05-12       Impact factor: 41.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.